Gavint Malenfant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Expanded management team to lead development programs with special focus on PMN310 for Alzheimer's diseaseTORONTO and CAMBRIDGE, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX:

United statesSan diegoUnited kingdomElliot goldsteinGavint malenfantDennis chenEugene williamsNicholas rigopulosMichael grundmanErnestd bushUniversity of californiaBiopharmaceutical developmentCentral nervous system advisory committeePromis neurosciences incRegulatory affairsAlzheimer disease cooperative study